GLOW Peptide

GLOW peptide, in brief. Rebuilding damaged tissue is not one job but a sequence: get blood to the injury, get cells to move in and build new vessels, then lay down the collagen scaffold that makes the repair hold. GLOW puts three peptides in one vial, and each has its own preclinical literature on a different part of that sequence. GHK-Cu, a copper-binding tripeptide found in plasma, is the one studied for the collagen stage; in fibroblast cultures it drove collagen synthesis at picomolar concentrations [2]. BPC-157, a 15-residue fragment of a gastric protein, is studied for blood supply and the earliest response to injury [5]. TB-500, synthetic full-length thymosin beta-4, is studied for getting cells to move into a wound and for new vessel growth; in a rat wound model it increased skin regrowth by up to 61% at day 7 [9]. What the three do together is unknown, because no published study has tested the combination, and that is why GLOW is a research tool rather than a characterized formulation. NextGenPeps supplies it for laboratory use only.

What does GLOW do?

Each of the three is studied for making damaged tissue rebuild faster, and the vial simply holds all three at a fixed ratio. GLOW itself has not been studied as a single agent, so what follows is the record of the components, not of the blend.

Between them the three cover different stages of healing: blood supply and the early response to injury, cell movement and new blood vessel growth, and rebuilding the extracellular matrix, the scaffold of collagen and related molecules that holds tissue together.

What the mixture itself does is unknown. No peer-reviewed study has tested the three peptides in combination.

How does GLOW work?

The rationale for combining the three is that tissue repair runs in overlapping stages, and each peptide has been studied in a different one (Figure 1). BPC-157 work concentrates on blood supply and the early response to injury [5]. Thymosin beta-4 work concentrates on cell movement into the wound and new vessel growth [8,9]. GHK-Cu work concentrates on rebuilding the extracellular matrix: collagen, glycosaminoglycans and the enzymes that remodel them [2,3].

Figure 1. Where each component sits in the repair sequence. A simplification of the stages each peptide has been studied in, in cell and animal models. The arrows show the order of repair stages, not proven interactions between the peptides.

What the combination does and does not show. The case for GLOW rests on each component's separate literature. No peer-reviewed study has tested BPC-157, TB-500 and GHK-Cu together, so any additive or synergistic effect of the blend is a hypothesis to test, not a finding.

Why researchers use a blend

The three peptides are packed into one vial so that a protocol can deliver all three together at a fixed ratio. That suits designs meant to test the combination rather than any single component.

GLOW research: what the evidence covers

The three components sit at very different stages of evidence (Figure 2). GHK-Cu has the longest history, with decades of cell and animal work and use in topical cosmetics. Thymosin beta-4 has gone furthest clinically, with phase 2 trials of topical and eye-drop formulations. BPC-157 has a large rodent literature, mostly from a single research group, and almost no controlled clinical data. The blend itself has no published studies at all.

Figure 2. Published evidence by component. Filled cells mark at least one peer-reviewed study of that type. "Human" means controlled clinical data except where noted. The GLOW combination has none.

Is GLOW peptide legal? Regulatory status in 2026

None of the three components is an FDA-approved drug. On April 15, 2026, the FDA said it would remove twelve peptides, including BPC-157, TB-500 (defined there as the LKKTETQ fragment rather than the full-length protein in GLOW) and injectable GHK-Cu, from Category 2 of its interim list of bulk substances that raise significant safety concerns for pharmacy compounding. Removal did not place them on the list of substances that may be compounded [11]. At its July 23, 2026 meeting, the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding BPC-157 and the TB-500 fragment to that list; injectable GHK-Cu is due for a separate review before the end of February 2027. The votes are not binding, and FDA must still complete rulemaking before anything changes [12].

For sport, the World Anti-Doping Agency prohibits BPC-157 as a non-approved substance and thymosin beta-4 and its derivatives, including TB-500, as peptide hormones and growth factors [13].

GLOW vs KLOW

KLOW is the same three peptides plus a fourth, KPV, a three-residue fragment (Lys-Pro-Val) of alpha-melanocyte-stimulating hormone studied for anti-inflammatory activity. GLOW is the choice for protocols that study the repair components alone; KLOW adds an inflammation arm. Like GLOW, the four-peptide combination has no published studies of its own.

What is GLOW peptide made of?

GLOW is not a single molecule. It is a fixed-ratio combination of three separate peptides, each studied for a different part of the repair process. The name is a supplier convention, not a scientific one, and different vendors use different ratios.

The NextGenPeps vial comes in two sizes. The 70 mg vial holds 50 mg of GHK-Cu, 10 mg of BPC-157 and 10 mg of TB-500. The 50 mg vial holds 30 mg of GHK-Cu, 10 mg of BPC-157 and 10 mg of TB-500 (Figure 3).

The two sizes differ only in GHK-Cu. Both carry the same amount of BPC-157 and TB-500. In both, GHK-Cu makes up most of the mass, and because it is by far the smallest of the three molecules it also makes up the large majority of the molecules in the vial.

Figure 3. What is in each GLOW vial. Stated content per vial by component. GHK-Cu is 71% of the 70 mg vial and 60% of the 50 mg vial by mass. Each lot's certificate of analysis reports measured purity for the blend.

What are the three components?

GHK-Cu (copper tripeptide)

This is the component studied for the rebuilding stage, where collagen and the surrounding scaffold are laid down. GHK is the tripeptide glycyl-L-histidyl-L-lysine. Pickart first isolated it from human plasma in 1973, where it carries copper(II) with high affinity [1]. In fibroblast cultures the copper complex stimulated collagen synthesis at picomolar to nanomolar concentrations [2]. Later gene-expression analyses found that GHK shifts the activity of a large share of human genes, many of them involved in tissue remodeling, antioxidant defence and inflammation [4]. GHK-Cu is also a long-standing cosmetic ingredient in topical skin products.

BPC-157 (body protection compound 157)

This is the component studied for blood supply and the earliest response to an injury. BPC-157 is a synthetic pentadecapeptide, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, taken from a partial sequence of a protein in human gastric juice. It is unusually stable in gastric juice for a peptide. Almost all of its literature comes from rodent and cell models, where it has been linked to blood vessel formation and the nitric oxide system [5]. In cultured tendon fibroblasts it increased outgrowth, survival under oxidative stress and cell migration [6]. Clinical data are limited to small uncontrolled reports, such as a retrospective review of intra-articular injections for knee pain [7].

TB-500 (thymosin beta-4)

This is the component studied for getting cells to move into a wound and for new blood vessels forming there. Thymosin beta-4 is a 43-residue protein present in almost every cell, where it binds and stores actin monomers, the building blocks of the cell's internal scaffolding. Outside the cell it has been linked to cell migration, new blood vessel growth and lower inflammation [8]. In a rat full-thickness wound model, thymosin beta-4 increased re-epithelialization by 42% at day 4 and by up to 61% at day 7 compared with saline [9]. Small phase 2 trials have tested topical thymosin beta-4 in chronic skin wounds without establishing efficacy [10].

The TB-500 in GLOW is synthetic full-length thymosin beta-4, all 43 residues, with its identity confirmed by mass spectrometry on each lot's certificate of analysis. The name is not used consistently: the FDA's 2026 compounding notice uses "TB-500" for the seven-residue fragment LKKTETQ, the actin-binding stretch of the protein [11]. Results reported for "TB-500" elsewhere may refer to either molecule.

Buying GLOW for research: what each vial includes

Because GLOW is a blend, the useful documentation is per lot and per component. Every GLOW lot is tested by an independent laboratory, and the certificate of analysis is published in the NextGenPeps COA library.

• 70 mg vial. Identity by LC-MS/MS, purity by RP-HPLC (99.71%), content by HPLC quantitation, and endotoxin under 0.05 EU/mL by USP <85> (Bioviridian, September 25, 2026).

• 50 mg vial. Identity and purity by UHPLC-MS, reported per component at 99.66%, 99.80% and 99.72% (Bioregen, January 15, 2026).

• Fulfilment. Orders ship within 24 hours from the United States, with free US shipping on orders over $150.

• Research use only. GLOW is sold strictly for in vitro and approved animal research. It is not for human or veterinary use and is not sold as a drug, cosmetic, supplement or diagnostic.

GLOW handling, storage and analytical notes

Format. Supplied as lyophilized powder in a sealed vial and reconstituted with sterile or bacteriostatic water before use. No dosing instructions are supplied, and none should be inferred from the studies above.

Color. GHK-Cu is blue, so GLOW powder and solution are blue to violet. A noticeably different color is a reason to check the lot.

Ratios after reconstitution. All three components dissolve together, so every withdrawal carries the same fixed ratio. A protocol that needs to vary one component independently needs the single peptides instead.

Compatibility. Copper(II) binds strongly to GHK, but free copper can interact with other molecules. Keep GLOW solutions separate from reducing agents and chelators such as EDTA, which can strip copper from the complex.

What is not yet established about GLOW

• Whether the combination does anything the parts do not. No study has compared the blend with its components alone.

• Stability of the components together. Published stability work covers each peptide alone, not mixed with copper(II) in one solution.

• Clinical data. Apart from topical GHK-Cu and small thymosin beta-4 trials, controlled clinical data on the components are scarce, and none exist for the blend.

• Which TB-500 a study used. The name covers both full-length thymosin beta-4, which is what GLOW contains, and the LKKTETQ fragment, so published "TB-500" results are not automatically comparable.

Research Use Only. The statements made within this website have not been evaluated by the US Food and Drug Administration. These materials are not intended to diagnose, treat, cure or prevent any disease and are not intended for human or veterinary use. Studies described on this page are reported for scientific context and are not guidance of any kind.